Avecho Biotechnology (ASX:AVE) reported Friday that its 2024 loss narrowed to AU$0.001 per diluted share from AU$0.0015 a year earlier.
Total revenue for the 12 months ended Dec. 31, 2024, was AU$1.1 million, compared with AU$473,551 a year earlier.
The company's shares were down 14% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.